ORYZON achieves milestone in the clinical development of ORY-1001
BARCELONA, SPAIN / CAMBRIDGE MA
Oryzon Genomics has finalized the multiple ascending dose (MAD) stage of its Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics of ORY-1001 in patients with relapsed or refractory acute leukemia (AL). ORY-1001 is a potent and selective inhibitor of Lysine Specific Demethylase 1 (LSD1). Through the establishment of a Recommended Dose (RD) of ORY-1001, Oryzon has achieved this development milestone included in the License Agreement with Roche signed in April 2014 and will receive a payment of USD 4 million.